RASAL2 and breast cancer: Instead, Feng et al.16 showed that RASAL2 was overexpressed in a subset of triple-negative or estrogen receptor-negative (ER-negative) breast tumors, and activated small GTPase RAC1 signaling to drive mesenchymal invasion and metastasis, indicating its context dependency in breast cancer.